Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibitors: A new era of targeted therapy.

Maturitas - 1 May 2015

Tangutoori Shifalika, Baldwin Paige, Sridhar Srinivas

Abstract excerpt

Personalized medicine seeks to utilize targeted therapies with increased selectivity and efficacy in preselected patient cohorts. One such molecularly targeted therapy is enabled by inhibiting the enzyme poly(ADP-ribose) polymerase (PARP) by small molecule inhibitors in tumors which have a defect in the homologous DNA recombination pathway, most characteristically due to BRCA mutations. Olaparib, a highly potent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Molecular Targeted Therapy

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Precision Medicine

Source

Identifiers

PMID: 25708226
DOI: 10.1016/j.maturitas.2015.01.015

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitors: A new era of targeted therapy.PMID 25708226Read ↗

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targetingSemantic proximity Read ↗

The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer TreatmentSemantic proximity Read ↗

Advances in PARP inhibitors for the treatment of breast cancer.Semantic proximity Read ↗

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancerSemantic proximity Read ↗

Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future DevelopmentSemantic proximity Read ↗

Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature ReviewSemantic proximity Read ↗

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.Semantic proximity Read ↗

Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.Semantic proximity Read ↗

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.Semantic proximity Read ↗

An update on PARP inhibitors for the treatment of cancerSemantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

Parp Inhibitors for the Treatment of Ovarian CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.